Novartis Signs a License Agreement with Mesoblast to Develop and Commercialize Remestemcel-L for ARDS

November 20, 2020 Auto Bot Agreement, Biotech, Commercialize, Develop, Manufacture, Novartis, Signs, Treatment 0

Shots:

  • Mesoblast to receive $25M up front and $25M as equity investment with additional payments and royalties on achievement of development, regulatory and commercial milestones
  • Novartis to acquire the exclusive WW rights to develop, commercialize & manufacture remestemcel-L for ARDS & access to a cell-therapy based platform with WW rights to a range of potential indications. Novartis has the option to distribute remestemcel-L for GVHD (outside Japan)
  • Both parties have rights to co-fund development & commercialization for other non-respiratory indications. Remestemcel-L is currently being studied in COVID-19-related ARDS in an ongoing P-III study while Novartis plans to initiate a P-III study in non-COVID-19-related ARDS

Click here ­to­ read full press release/ article | Ref: Novartis | Image: Market Watch

The post Novartis Signs a License Agreement with Mesoblast to Develop and Commercialize Remestemcel-L for ARDS first appeared on PharmaShots.